The Technical AnalystExchange: EURONEXT Industry: Biotechnology
Cellectis SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.11% $2.65
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 189.78 mill |
| EPS: | -1.770 |
| P/E: | -1.490 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 71.75 mill |
| Avg Daily Volume: | 0.0959 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.490 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.490 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.763 (-71.16%) $-1.882 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.53 - 2.77 ( +/- 4.42%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.65 (-3.11% ) |
| Volume | 0.0697 mill |
| Avg. Vol. | 0.0959 mill |
| % of Avg. Vol | 72.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALCLS.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALCLS.PA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.